Clinical trial research
The team is dedicated to integrated evidence research for the transformation of traditional Chinese medicine (TCM) achievements, aiming to promote the organic integration of classical TCM theories with modern scientific methodologies and to enhance the scientific rigor of TCM drug development and clinical application. Key research directions include: providing systematic evidence to support the development of new compound Chinese medicines under the “three-in-one” evaluation framework, with a focus on scientific validity and clinical applicability; investigating symptom clusters and syndrome evolution in pulmonary epidemic diseases to construct a decision support system for medication based on disease progression patterns; conducting evidence-based research in health policy to assess the effectiveness of TCM policy implementation, providing scientific support for policy formulation and optimization. In addition, the team collaborates with China Unicom Smart Healthcare Technology Co., Ltd. to build a trustworthy evidence-based data space network for TCM. This initiative aims to establish unified standards for data collection, storage, transmission, and analysis; create a data resource repository with distinct TCM characteristics; ensure secure data sharing; and promote collaboration among medical institutions, research organizations, and pharmaceutical companies, ultimately enabling full-process data integration and value mining from clinical practice to drug development.
Contact email: cheqianzi@ccebtcm.org.cn
Evidence-based guidelines and consensus
The team has accumulated extensive experience in both international and localized development of clinical practice guidelines for TCM, and has pioneered the formulation of several landmark, first-of-their-kind guidelines. These include the first evidence-based clinical practice guideline for TCM, the first guideline for the diagnosis and treatment of common internal medicine diseases in TCM (covering both TCM syndromes and Western medical diseases), and the first batch of TCM guidelines for the Hong Kong region. In response to the COVID-19 pandemic, the team promptly led the development of a series of TCM guidelines, which were endorsed by Academician Yongyan WANG and included in the international Guidelines International Network (GIN) database. In addition, the team is committed to establishing common technical methodologies and promotion models for multi-scenario clinical practice guideline development. This includes the formulation of methodological standards for various types of guidelines, such as rapid dynamic TCM guidelines for public health emergencies, high-demand clinical guidelines for Chinese patent medicines, and patient-centered guidelines that highlight patient values and preferences. The team also conducts research on the clinical applicability and implementability of these guidelines.
Contact email:liangning@ccebtcm.org.cn
Contact email:liangning@ccebtcm.org.cn
Health technology assessment
The team is engaged in health technology assessment research of Chinese patent medicines. In response to the practical challenges and needs arising in the formulation and implementation of national drug policies, the team is committed to generating evidence to support national drug access policies, hospital drug selection, and rational clinical medication use. The goal is to provide recommendations for evidence-based decision-making in public health and refined drug management. The team has undertaken a key technical task outlined in the Opinions of the CPC Central Committee and the State Council on Promoting the Inheritance and Innovative Development of TCM, specifically the screening of 50 disease areas where TCM shows therapeutic advantages, 100 appropriate technologies, and 100 uniquely effective Chinese medicines. The team operates and manages several platforms, including the Comprehensive Evaluation Evidence and Achievement Transformation Platform of TCM and a multidimensional, multi-criteria data platform for the health technology assessment research of Chinese patent medicines. The team also manage the Intelligent Decision-Making Sub-Association for the Comprehensive Evaluation of TCM under The China Information Association of TCM—the only such subcommittee in China under a national-level academic organization in the field of TCM health technology assessment. The team has organized a multidisciplinary network involving 91 institutions across 16 provinces, municipalities, and autonomous regions, providing a strong foundation of talent, expert resources, and clinical support for the health technology assessment research of Chinese patent medicines.
Contact email:zhpj_office@163.com
Website:http://drug.stctcm.com/
Standards development and evaluation
The team focuses on the transformation of scientific and technological achievements into standards, with key efforts directed toward multidimensional evaluation of TCM standards at various levels, the development of standards across diverse TCM domains, and the provision of standardization training and technical consulting services. The team has established a full-cycle, dynamically optimized standardization pathway for TCM. Driven by research on common technical foundations in TCM standardization, the team aims to enhance the quality of service and management. The team has developed an authoritative TCM standards repository, which comprehensively includes international, national, industry, and group standards in TCM. Additionally, The team has built technical systems for standard proposal and formulation, evaluation, and implementation and application. The contributions include participation in the formulation of the industry standard General Principles for the Revision of TCM Syndrome Diagnosis and Therapeutic Effect Evaluation Standards (ZY/T 10—2024). The team’s evaluation results of TCM group standards has provided data support for the release of the Administrative Measures for TCM Group Standards. The team has authored the first ISO TCM international standard development guidebook, Guidelines for Developing ISO International Standards for TCM, and led the formulation of the first official submission standard for TCM international standards, Specifications for Submitting International Standards in TCM (T/CAS 766—2023).
Contact email:lihuizhen@ccebtcm.org.cn
Website:http://standards.ccebtcm.org.cn/
Contact email:lihuizhen@ccebtcm.org.cn
Website:http://standards.ccebtcm.org.cn/